Clinical Trial Update: Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045) [Phase 4]

View source ↗

Summary

Phase 4 pediatric trial MK-0517-045 evaluates the safety of a three-day fosaprepitant regimen to prevent chemotherapy-induced nausea and vomiting. The study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• FOSAPREPITANT (FOSAPREPITANT DIMEGLUMINE)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chemotherapy-induced Nausea and Vomiting | Phase 4 | Status: COMPLETED | Results posted: 2021-09-23